CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Interpace Biosciences Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Interpace Biosciences Inc
Waterview Plaza
Suite 310, 2001 Route 46
Phone: (412) 224-6100p:412 224-6100 PARSIPPANY, NJ  07054  United States Ticker: IDXGIDXG
On February 28, 2025, Interpace Biosciences, Inc., in discussions with EisnerAmper LLP, the company’s independent registered public accounting firm responsible for auditing its financial statements, determined that it will be required to restate its previously issued financial statements contained in the company’s Annual Report on Form 10-K for the year ended December 31, 2023 as well as the financial statements contained in the company’s quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2024 and March 31, 2023, June 30, 2024 and June 30, 2023, and September 30, 2024 and September 30, 2023 to effect reversals of accrued royalties expenses. Accordingly, investors should no longer rely upon such financial statements. The reversal of accrued royalties expense is a result of the company’s determination that the accrual of such royalties expenses was not required. The reversal is expected to have a positive impact on various financial statement items, including current liabilities, stockholders’ equity (deficit) and net income.
Business Summary
Interpace Biosciences, Inc. provides esoteric molecular diagnostic testing and pathology services to aid physicians in the evaluation of cancer risk. The Company’s clinical services business commercializes clinically useful molecular diagnostic tests and molecular pathology services. The Company develops and commercializes genomic tests and related first-line assays that can personalize medicine to help improve patient diagnosis and management. It has five commercialized molecular diagnostic tests: PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR v2, and RespriDX. PancraGEN is a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians’ better risk-stratify pancreaticobiliary cancers using the Company’s proprietary PathFinderTG platform. PanDNA is an alternate reporting option of the PathFinderTG platform, which provides physicians the molecular only information. ThyGeNEXT is an oncogenic mutation panel that helps rule-in and rule-out malignancy in thyroid nodules.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024YesYes--Yes

Industries
SIC Code Description
7389 Business services, not elsewhere classified
8071 Medical laboratories
2835 In vitro and in vivo diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman, President, Chief Executive Officer Thomas W.Burnell 62 2/1/2024 12/1/2020
Chief Financial Officer ChristopherMccarthy 33 7/24/2023 7/24/2023
Independent Director VijayAggarwal 75 2/1/2022 2/1/2022
3 additional Officers and Directors records available in full report.

Business Names
Business Name
IDXG
Interpace Diagnostics Lab Inc.
Interpace Diagnostics, LLC
Interpace Pharma Solutions, Inc.
miRInform Pancreas
miRInform Thyroid

General Information
Number of Employees: 111 (As of 3/21/2025)
Outstanding Shares: 4,423,093 (As of 3/21/2025)
Shareholders: 184
Stock Exchange: OTC
Federal Tax Id: 222919486
Fax Number: (302) 636-5454
Email Address: Scotugno@pdi-inc.com


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 18, 2025